ライフサイエンスコーパス: variant Creutzfeldt-Jakob disease

1 us 1, hepatitis C virus, enterovirus 70, and variant Creutzfeldt-Jakob disease.

2 d from human beings affected by sporadic and variant Creutzfeldt-Jakob disease.

3 case of bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease.

4 this could lead to a more virulent strain of variant Creutzfeldt-Jakob disease.

5 of prion disease in humans were diagnosed as variant Creutzfeldt-Jakob disease.

6 s a source of human-to-human transmission of variant Creutzfeldt-Jakob disease.

7 m those observed in sporadic, iatrogenic and variant Creutzfeldt-Jakob disease.

8 e methionine homozygote to both sporadic and variant Creutzfeldt-Jakob disease.

9 ease) or can be acquired, as is the case for variant Creutzfeldt-Jakob disease.

10 tissues in a unique series of nine cases of variant Creutzfeldt-Jakob disease.

11 laria, severe acute respiratory syndrome, or variant Creutzfeldt-Jakob disease.

12 iform encephalopathy (BSE) prions causes new variant Creutzfeldt-Jakob disease.

13 al targets for therapy, for example, in 'new variant' Creutzfeldt-Jakob disease.

14 RNP MV genotype individual can propagate the variant Creutzfeldt-Jakob disease agent and that the inf

15 d the possibility that the properties of the variant Creutzfeldt-Jakob disease agent could change aft

16 onsistently demonstrated transmission of the variant Creutzfeldt-Jakob disease agent.

17 the PrP(Sc) that accumulates in the brain in variant Creutzfeldt-Jakob disease also contains a minori

18 ined from human post-mortem samples, of both variant Creutzfeldt-Jakob disease and Alzheimer's diseas

19 e chronic human neurodegenerative conditions variant Creutzfeldt-Jakob disease and Alzheimer's diseas

20 sions from donors who subsequently developed variant Creutzfeldt-Jakob disease and an asymptomatic re

21 etectable only in the urine of patients with variant Creutzfeldt-Jakob disease and had the typical el

22 14 urine samples obtained from patients with variant Creutzfeldt-Jakob disease and in none of the 224

23 nce that either Creutzfeldt-Jakob disease or variant Creutzfeldt-Jakob disease are transmitted by tra

24 issible spongiform encephalopathies, such as variant Creutzfeldt-Jakob disease, are believed to resul

25 ly 10(5)-fold dilution of 10% (wt/vol) human variant Creutzfeldt-Jakob disease brain homogenate, with

26 phoreticular system is a defining feature of variant Creutzfeldt-Jakob disease, but that the biochemi

27 eview focuses on transfusion-transmission of variant Creutzfeldt-Jakob disease by red cell preparatio

28 covered by this review, the transmission of variant Creutzfeldt-Jakob disease by transfusion has bee

29 tion as a precaution against transmission of variant Creutzfeldt-Jakob disease by transfusion of dome

30 Recent evidence that variant Creutzfeldt-Jakob disease can be transmitted by

31 iod makes it difficult to predict future new variant Creutzfeldt-Jakob disease case numbers; further

32 terest, and findings were followed-up in six variant Creutzfeldt-Jakob disease cases with 9.4 T high-

33 infection parameters from a UK cohort of 171 variant Creutzfeldt-Jakob disease cases.

34 In an effort to prevent new variant Creutzfeldt-Jakob disease, certain "specified of

35 spongiform encephalopathy (BSE) to humans as variant Creutzfeldt-Jakob disease (CJD) has affected ove

36 Variant Creutzfeldt-Jakob disease (CJD) is thought to be

37 ine spongiform encephalopathy to people as a variant Creutzfeldt-Jakob disease (CJD), it becomes crit

38 sting itself as a novel human prion disease, variant Creutzfeldt-Jakob disease (CjD).

39 ) has been done aside from a small sample of variant Creutzfeldt-Jakob disease (CJD).

40 to be susceptible to prions from humans with variant Creutzfeldt-Jakob disease (CJD); on second passa

41 'New variant' Creutzfeldt-Jakob disease (CJD) has strain char

42 Urine samples obtained from patients with variant Creutzfeldt-Jakob disease contained minute quant

43 Back-calculation analysis of the variant Creutzfeldt-Jakob disease epidemic in the United

44 ablish whether the strain characteristics of variant Creutzfeldt-Jakob disease had been modified by t

45 The recent emergence of variant Creutzfeldt-Jakob disease has led to major publi

46 The outbreak of new variant Creutzfeldt-Jakob disease has raised the specter

47 ll transfusion recipient, who did not die of variant Creutzfeldt-Jakob disease, has been identified w

48 Three cases of variant Creutzfeldt-Jakob disease have been identified f

49 all previous definite and probable cases of variant Creutzfeldt-Jakob disease have been methionine h

50 form encephalopathy to humans in the form of variant Creutzfeldt Jakob disease, have raised concerns

51 In 2004, a subclinical case of variant Creutzfeldt-Jakob disease in a PRNP 129 methioni

52 naturally occurring scrapie in sheep and of variant Creutzfeldt-Jakob disease in humans.

53 fection for three individuals diagnosed with variant Creutzfeldt-Jakob disease in the USA and Canada.

54 compared with other transmission studies in variant Creutzfeldt-Jakob disease, including those on th

55 ntial for significant numbers of subclinical variant Creutzfeldt-Jakob disease individuals in at leas

56 n strain modification, the identification of variant Creutzfeldt-Jakob disease infection in a PRNP 12

57 New variant Creutzfeldt-Jakob disease is a novel human prion

58 analysis of prion strains suggests that new variant Creutzfeldt-Jakob disease is caused by BSE expos

59 ditions of humans and animals, one of which (variant Creutzfeldt-Jakob disease) is known to be a zoon

60 A novel acquired human prion disease, variant Creutzfeldt-Jakob disease, is thought to result

61 tudy of PrP(Sc) from autopsy-proved cases of variant Creutzfeldt-Jakob disease (n = 59) and compare t

62 All tested cases of new variant Creutzfeldt-Jakob disease (nvCJD) have been homo

63 , 1998, 35 deaths had been attributed to new variant Creutzfeldt-Jakob disease (nvCJD) in the United

64 There was no evidence of any death from variant Creutzfeldt-Jakob disease or from conditions tha

65 Risk assessments for transmission of variant Creutzfeldt-Jakob disease predicted that leukocy

66 Strikingly, prion seeding activity in variant Creutzfeldt-Jakob disease prion-exposed human Pr

67 kdown of Hsp110 or DnaJ-1 gene expression in variant Creutzfeldt-Jakob disease prion-exposed human Pr

68 In variant Creutzfeldt-Jakob disease, prion replication is

69 Evidence suggests that variant Creutzfeldt-Jakob disease prions circulate in bo

70 polymorphic codon in humans associated with variant Creutzfeldt-Jakob disease, pulls the N terminus

71 s) in lymphoid tissues of patients with 'new variant' Creutzfeldt-Jakob disease, sheep with natural s

72 The variant Creutzfeldt-Jakob disease strain has to date bee

73 Thus we have demonstrated variant Creutzfeldt-Jakob disease strain properties are

74 indicates a single PrP(Sc) molecular type in variant Creutzfeldt-Jakob disease (termed type 2B), pres

75 type 1 PrP(Sc) was found in all 21 cases of variant Creutzfeldt-Jakob disease tested, irrespective o

76 As of mid-2016, 231 cases of variant Creutzfeldt-Jakob disease-the human form of a pr

77 The results show PrP(Sc) in variant Creutzfeldt-Jakob disease to be remarkably stere

78 region examined, and was also present in the variant Creutzfeldt-Jakob disease tonsil.

79 s our current understanding of the risks of (variant) Creutzfeldt-Jakob disease transmission via dent

80 vidual were totally consistent with those of variant Creutzfeldt-Jakob disease transmitted to 129 met

81 Variant Creutzfeldt-Jakob disease (variant CJD) is diffi

82 The agent that causes variant Creutzfeldt-Jakob disease (variant CJD) is indis

83 Variant Creutzfeldt-Jakob disease (vCJD) and bovine spon

84 causes the fatal neurodegenerative condition variant Creutzfeldt-Jakob disease (vCJD) and, based on r

85 Our study indicates a prototype blood-based variant Creutzfeldt-Jakob disease (vCJD) assay has suffi

86 ical instruments from, a deceased carrier of variant Creutzfeldt-Jakob disease (vCJD) can be followed

87 humans, as a result of the rising number of variant Creutzfeldt-Jakob disease (vCJD) cases.

88 Variant Creutzfeldt-Jakob disease (vCJD) differs from ot

89 Variant Creutzfeldt-Jakob disease (vCJD) has a pathogene

90 Variant Creutzfeldt-Jakob disease (vCJD) has been recogn

91 Person-to-person transmission of variant Creutzfeldt-Jakob disease (vCJD) has occurred th

92 Infections with variant Creutzfeldt-Jakob disease (vCJD) have almost exc

93 A small number of patients with variant Creutzfeldt-Jakob disease (vCJD) have been treat

94 We report a case of preclinical variant Creutzfeldt-Jakob disease (vCJD) in a patient wh

95 rion disease reputed to be zoonotic, causing variant Creutzfeldt-Jakob disease (vCJD) in humans and h

96 ings are relevant to the current outbreak of variant Creutzfeldt-Jakob disease (vCJD) in the United K

97 The development of variant Creutzfeldt-Jakob disease (vCJD) in three recipi

98 sheep for relative human exposure levels and variant Creutzfeldt-Jakob disease (vCJD) incidence.

99 Variant Creutzfeldt-Jakob disease (vCJD) is a devastatin

100 Variant Creutzfeldt-Jakob disease (vCJD) is a fatal neur

101 Variant Creutzfeldt-Jakob disease (vCJD) is a fatal neur

102 Variant Creutzfeldt-Jakob disease (vCJD) is a novel huma

103 Variant Creutzfeldt-Jakob disease (vCJD) is a unique and

104 sceptibility to, and clinical expression of, variant Creutzfeldt-Jakob disease (vCJD) is essential fo

105 Concerns have been raised that variant Creutzfeldt-Jakob disease (vCJD) might be transm

106 eographical variation in the distribution of variant Creutzfeldt-Jakob disease (vCJD) might indicate

107 ortex samples, from prion-affected patients (variant Creutzfeldt-Jakob disease (vCJD) n = 20, iatroge

108 f bovine spongiform encephalopathy (BSE) and variant Creutzfeldt-Jakob disease (vCJD) prions are fait

109 The transmission of variant Creutzfeldt-Jakob disease (vCJD) through blood t

110 appear to be a reservoir for transmission of variant Creutzfeldt-Jakob disease (vCJD) to humans.

111 Interindividual variant Creutzfeldt-Jakob disease (vCJD) transmission th

112 e an increasing concern since the reports of variant Creutzfeldt-Jakob disease (vCJD) transmission th

113 Estimates for the risk of transmitting variant Creutzfeldt-Jakob disease (vCJD) via blood trans

114 Identification of possible transmission of variant Creutzfeldt-Jakob disease (vCJD) via blood trans

115 Variant Creutzfeldt-Jakob disease (vCJD) was first descr

116 Variant Creutzfeldt-Jakob Disease (vCJD) was first repor

117 Variant Creutzfeldt-Jakob disease (vCJD), a novel form o

118 on (PMCA) in urine of patients affected with variant Creutzfeldt-Jakob disease (vCJD), a prion diseas

119 The onset of variant Creutzfeldt-Jakob disease (vCJD), and the unknow

120 cephalopathy (BSE) and its human equivalent, variant Creutzfeldt-Jakob disease (vCJD), are caused by

121 sfusion has been described in cases of human variant Creutzfeldt-Jakob disease (vCJD), experimental o

122 is C, bovine spongiform encephalopathy (BSE)/variant Creutzfeldt-Jakob disease (vCJD), Nipah virus, s

123 centers in lymphoid tissues of patients with variant Creutzfeldt-Jakob disease (vCJD), sheep with nat

124 an accurate non-invasive diagnostic test for variant Creutzfeldt-Jakob disease (vCJD).

125 veys to detect clinically silent carriers of variant Creutzfeldt-Jakob disease (vCJD).

126 phalopathy (BSE) prions, the causal agent of variant Creutzfeldt-Jakob disease (vCJD).

127 e neuropsychological profile associated with variant Creutzfeldt-Jakob disease (vCJD).

128 We report a case of variant Creutzfeldt-Jakob disease(vCJD) in a 74-year old

129 Transmission of variant Creutzfeldt-Jakob disease was observed from the

130 ce between PrP(Sc) types was maintained when variant Creutzfeldt-Jakob disease was transmitted to wil

131 an be detected in the urine of patients with variant Creutzfeldt-Jakob disease, we used the protein m